Theravance Biopharma Inc
NASDAQ:TBPH
P/OCF
Price to OCF
Price to Operating Cash Flow (P/OCF) ratio is a valuation multiple that measures the value of a company’s market capitalization relative to the operating cash flow it generates. Some analysts prefer P/OCF over P/E since earnings can be more easily manipulated than cash flows.
Market Cap | P/OCF | ||||
---|---|---|---|---|---|
KY |
Theravance Biopharma Inc
NASDAQ:TBPH
|
451.1m USD | -16.7 | ||
JP |
N
|
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
|
776 550.9T JPY | -19 905 436.7 | |
US |
Eli Lilly and Co
NYSE:LLY
|
722.3B USD | 196.5 | ||
DK |
Novo Nordisk A/S
CSE:NOVO B
|
4T DKK | 43.1 | ||
UK |
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP | 6 923.9 | ||
US |
Johnson & Johnson
NYSE:JNJ
|
360.8B USD | 15.6 | ||
US |
Merck & Co Inc
NYSE:MRK
|
329.4B USD | 22.3 | ||
UK |
AstraZeneca PLC
LSE:AZN
|
191.1B GBP | 24.7 | ||
CH |
Novartis AG
SIX:NOVN
|
181.1B CHF | 14.5 | ||
CH |
Roche Holding AG
SIX:ROG
|
180B CHF | 11.2 | ||
US |
Pfizer Inc
NYSE:PFE
|
158.1B USD | 18.2 |
P/OCF Forward Multiples
Forward P/OCF multiple is a version of the P/OCF ratio that uses forecasted operating cash flow for the P/OCF calculation. 1-Year, 2-Years, and 3-Years forwards use operating cash flow forecasts for 1, 2, and 3 years ahead, respectively.